Compare Flagstar Bank NA (FLG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Summit Therapeutics Inc — how do they compare? Flagstar Bank NA trades at $11.37 (market cap $4.71B), while Summit Therapeutics Inc trades at $17.42 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2.9× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and Summit Therapeutics Inc for 16 Days on average.
| FLG | SMMT | |
|---|---|---|
Market Cap | $4.71B | $13.71B |
Volume | 7,410,589 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $15.36 | $26.38 |
52-Week Low | $10.72 | $12.43 |
Typical Hold Time | 21 Days | 16 Days |
Enterprise Value | $15.25B | $13.04B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.21, down 0.8% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but attractive P/B of 0.62, while transitioning from a $177M loss in 2025 to profitability in 2026. Recent news highlights strategic partnerships and a $250M share repurchase program, though Q2 2026 earnings missed expectations.
Analyst consensus remains bullish with a $17.07 price target (60% buy ratings), offering significant upside potential. Key risks include volatile cash flows and competitive banking pressures. The current discount to book value and institutional support suggest long-term value if profitability trends continue.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
